Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12661864 | 0.81 | CYP2C19 (0.41) | CYP2C19CYP1A2CYP2D6CYP2C9RXFP1 | |
| SCHEMBL29710403 | 0.81 | CYP2C19 (0.41) | CYP2C19CYP1A2CYP2D6CYP2C9RXFP1 | |
| SCHEMBL30592427 | 0.79 | KDM4E (0.33) | CYP2C19CYP1A2CYP2D6CYP2C9RXFP1 | |
| SCHEMBL16830030 | 0.79 | KDM4E (0.33) | CYP2C19CYP1A2CYP2D6CYP2C9RXFP1 | |
| SCHEMBL649387 | 0.76 | HPGD (0.37) | CYP2C19CYP1A2CYP2D6CYP2C9RXFP1 | |
| SCHEMBL31292178 | 0.75 | DPP4 (0.32) | LMNAKDM4E | |
| SCHEMBL30624534 | 0.71 | SMN1; SMN2 (0.43) | LMNAKDM4E | |
| SCHEMBL3706754 | 0.71 | KDM4E (0.37) | CYP2C19LMNAKDM4ECYP3A4HIF1A | |
| SCHEMBL7111689 | 0.70 | ALDH1A1 (0.37) | CYP2C19CYP1A2LMNAKDM4ECYP3A4 | |
| SCHEMBL11985880 | 0.70 | HTT (0.35) | CYP2C19LMNAKDM4ECYP3A4HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340528-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2025-11-06 | — | — | US | disclosed |
| US-12459920-B2 | Targeted protein degradation | MONTE ROSA THERAPEUTICS AG (CH) | 2025-11-04 | — | — | US | disclosed |
| US-20250243180-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2025-07-31 | — | — | US | disclosed |
| WO-2025024521-A1 | SUBSTITUTED PIPERIDINEDIONES FOR TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS, INC. (US) | 2025-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250243180-A1 | TARGETED PROTEIN DEGRADATION | NEK7, NEK1, RIPK1 | CYP2C19 4814/4885CYP1A2 4493/4885CYP2D6 4805/4885 |
| US-12459920-B2 | Targeted protein degradation | NEK7, NEK1, RIPK1 | CYP2C19 4816/4885CYP1A2 4503/4885CYP2D6 4807/4885 |
| US-20250340528-A1 | TARGETED PROTEIN DEGRADATION | NEK7, NEK1, RIPK1 | CYP2C19 4814/4885CYP1A2 4493/4885CYP2D6 4805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.